[HTML][HTML] Identification of 4 novel HLA-B* 40: 01 restricted minor histocompatibility antigens and their potential as targets for graft-versus-leukemia reactivity
M Griffioen, MW Honders, ED van der Meijden… - …, 2012 - ncbi.nlm.nih.gov
M Griffioen, MW Honders, ED van der Meijden, SAP van Luxemburg-Heijs, EGA Lurvink…
haematologica, 2012•ncbi.nlm.nih.govBackground Patients with hematologic malignancies can be successfully treated with donor
lymphocyte infusion after HLA-matched allogeneic hematopoietic stem cell transplantation.
The effect of donor lymphocyte infusion is mediated by donor T cells recognizing minor
histocompatibility antigens. T cells recognizing hematopoietic restricted minor
histocompatibility antigens may induce selective graft-versus-leukemia reactivity, whereas
broadly-expressed antigens may be targeted in graft-versus-host disease.
lymphocyte infusion after HLA-matched allogeneic hematopoietic stem cell transplantation.
The effect of donor lymphocyte infusion is mediated by donor T cells recognizing minor
histocompatibility antigens. T cells recognizing hematopoietic restricted minor
histocompatibility antigens may induce selective graft-versus-leukemia reactivity, whereas
broadly-expressed antigens may be targeted in graft-versus-host disease.
Abstract
Background
Patients with hematologic malignancies can be successfully treated with donor lymphocyte infusion after HLA-matched allogeneic hematopoietic stem cell transplantation. The effect of donor lymphocyte infusion is mediated by donor T cells recognizing minor histocompatibility antigens. T cells recognizing hematopoietic restricted minor histocompatibility antigens may induce selective graft-versus-leukemia reactivity, whereas broadly-expressed antigens may be targeted in graft-versus-host disease.
ncbi.nlm.nih.gov